Protalix BioTherapeutics (NYSE:PLX) Upgraded to “Strong-Buy” at StockNews.com

StockNews.com upgraded shares of Protalix BioTherapeutics (NYSE:PLX) from a buy rating to a strong-buy rating in a report issued on Thursday.

Protalix BioTherapeutics Price Performance

Shares of NYSE:PLX opened at $1.80 on Thursday. Protalix BioTherapeutics has a 1 year low of $0.82 and a 1 year high of $1.90. The company has a market capitalization of $132.54 million, a PE ratio of -13.85 and a beta of 0.74. The business has a fifty day moving average price of $1.37 and a two-hundred day moving average price of $1.18.

Hedge Funds Weigh In On Protalix BioTherapeutics

Institutional investors have recently bought and sold shares of the company. Squarepoint Ops LLC grew its stake in shares of Protalix BioTherapeutics by 673.3% during the 2nd quarter. Squarepoint Ops LLC now owns 137,764 shares of the company’s stock worth $161,000 after acquiring an additional 119,949 shares during the period. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Protalix BioTherapeutics during the second quarter valued at about $80,000. Ground Swell Capital LLC bought a new position in Protalix BioTherapeutics during the second quarter worth about $73,000. AQR Capital Management LLC purchased a new position in Protalix BioTherapeutics in the 2nd quarter valued at approximately $67,000. Finally, Virtu Financial LLC bought a new position in shares of Protalix BioTherapeutics in the third quarter worth $44,000. Hedge funds and other institutional investors own 16.53% of the company’s stock.

Protalix BioTherapeutics Company Profile

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.